FindTrial
Sign In

PT-112 Injection

DRUG2 trials

Sponsors

Promontory Therapeutics Inc., SciClone Pharmaceuticals

Conditions

Advanced Solid TumorsCRPCGenital Neoplasms, MaleMetastatic Castrate-resistant Prostate CancerNeoplasms by SitePT-112Prostatic NeoplasmsUrogenital Neoplasms

Phase 1

An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma
NCT03439761
SciClone PharmaceuticalsAdvanced Solid Tumors
Start: 2018-03-07End: 2020-07-31Target: 125Updated: 2018-03-16

Phase 2

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Active, not recruitingNCT02266745
Promontory Therapeutics Inc.Advanced Solid Tumors, CRPC, Genital Neoplasms, Male +6
Start: 2014-07-31End: 2025-04-01Target: 109Updated: 2024-04-05

Related Papers

Preliminary phase 2 results of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2025-05-28
Abstract 5819: Anti-cancer immune effects of PT-112 monotherapy across two disease indications
Cancer Research2025-04-211 citations
A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology2023-02-204 citations
Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours.
2022-05-2720 citations
PT-112 in advanced metastatic castrate-resistant prostate cancer (mCRPC), as monotherapy or in combination with PD-L1 inhibitor avelumab: Findings from two phase I studies.
Journal of Clinical Oncology2020-02-1920 citations
A phase I study of PT-112 in advanced solid tumors.
Journal of Clinical Oncology2017-05-204 citations